静注免疫球蛋白联合更昔洛韦治疗病毒性脑膜炎的临床分析  

Clinical Analysis of Intravenous Immunoglobulin Combined with Ganciclovir in the Treatment of Viral Meningitis

作　　者：白银雪 BAI Yinxue(Department of Neurology,the First Affiliated Hospital of Nanyang Medical College,Nanyang,Henan 473000,China)

机构地区：[1]南阳医学高等专科学校第一附属医院神经内科,河南南阳473000

出　　处：《航空航天医学杂志》2021年第1期8-9,共2页Journal of Aerospace medicine

摘　　要：目的探讨静注免疫球蛋白联合更昔洛韦治疗病毒性脑膜炎的临床效果。方法选取2017年7月-2018年7月治疗的病毒性脑膜炎患者90例,按照随机抽签法分组,对照组45例,单独使用更昔洛韦治疗,观察组45例,用静注免疫球蛋白联合更昔洛韦治疗。对比两组治疗后白细胞因子水平及临床疗效。结果治疗前,两组白细胞介素-1、肿瘤坏死因子-α水平均无明显差异(P>0.05),治疗后,观察组白细胞介素-1、肿瘤坏死因子-α水平低于对照组(P<0.05)。观察组临床治疗有效率占比为97.8%,对照组临床治疗有效率占比为80.0%,两组差异明显(P<0.05)。结论静注免疫球蛋白联合更昔洛韦治疗病毒性脑膜炎,能够改善患者的白细胞介素-1、肿瘤坏死因子-α因子水平,临床疗效良好。Objective To explore the clinical effect of intravenous immunoglobulin combined with ganciclovir in the treatment of viral meningitis. Methods 90 patients with viral meningitis treated in our hospital from July 2017 to July 2018 were selected and grouped according to the random drawing method. The control group was 45 cases and was treated with ganciclovir alone. The observation group was 45 cases. Intravenous immunoglobulin combined with ganciclovir treatment. Compare the level of leukocyte factor and clinical efficacy of the two groups after treatment. Results Before treatment, there was no significant difference in the levels of interleukin-1 and tumor necrosis factor-α between the two groups(P>0.05). After treatment, the levels of interleukin-1 and tumor necrosis factor-α in the observation group were lower than those in the control group(P<0.05). The effective rate of clinical treatment in the observation group was 97.8%, and the effective rate of clinical treatment in the control group was 80.0%. The difference between the two groups was significant(P<0.05). Conclusions Intravenous immunoglobulin combined with ganciclovir in the treatment of viral meningitis can improve the levels of interleukin-1 and tumor necrosis factor-α factor in patients. The clinical effect is good and can be promoted.

关 键 词：病毒性脑膜炎 静注免疫球蛋白 更昔洛韦 白细胞介素-1、肿瘤坏死因子-α 

分 类 号：R512.3[医药卫生—内科学]